10-QPeriod: Q1 FY2014

QUEST DIAGNOSTICS INC Quarterly Report for Q1 Ended Mar 31, 2014

Filed May 1, 2014For Securities:DGX

Summary

Quest Diagnostics Inc. (DGX) reported financial results for the first quarter ended March 31, 2014. The company experienced a slight decrease in net revenues to $1.75 billion from $1.79 billion in the prior year period, primarily impacted by a challenging winter and a shift in service mix. Despite the revenue dip, operational efficiencies and cost management led to a controlled decrease in operating costs, with SG&A expenses notably declining. The company made significant strategic moves during the quarter, including the completion of the Solstas Lab Partners Group acquisition for $572 million, which is expected to expand its footprint in the southeastern United States. Quest Diagnostics also continued its commitment to returning value to shareholders through a 10% increase in its quarterly dividend and ongoing share repurchases. Management remains focused on its five-point strategy, emphasizing growth initiatives and operational excellence. While facing some headwinds from market conditions and integration costs, Quest Diagnostics demonstrated resilience through strategic acquisitions and effective cost controls. The company's focus on its core Diagnostic Information Services (DIS) business, combined with efforts to streamline operations, positions it to navigate the evolving healthcare landscape.

Financial Highlights

57 data points
Beta

Revenue

$1.75B

36.9% Gross Margin

Net Income

$104.00M

6.0% Net Margin

EPS (Diluted)

$0.71

Total Assets

$9.55B

Cash & Equivalents

$144.00M

Free Cash Flow

$16.00M

Financial Statements
Beta
Revenue$1.75B
Cost of Revenue$1.10B
Gross Profit$645.00M
SG&A Expenses$415.00M
Operating Expenses$1.54B
Operating Income$208.00M
Interest Expense$40.00M
Net Income$104.00M
EPS (Basic)$0.72
EPS (Diluted)$0.71
Shares Outstanding (Basic)144.00M
Shares Outstanding (Diluted)145.00M

Key Highlights

  • 1Net revenues for the first quarter of 2014 decreased by 2.3% to $1.75 billion compared to $1.79 billion in the prior year.
  • 2The company completed the acquisition of Solstas Lab Partners Group for $572 million, enhancing its presence in the southeastern United States.
  • 3Income from continuing operations attributable to Quest Diagnostics' stockholders decreased by 10.3% to $104 million, resulting in diluted EPS of $0.71.
  • 4Selling, General, and Administrative (SG&A) expenses decreased by 7.4% due to cost management and workforce reductions.
  • 5The company increased its quarterly cash dividend by 10% to $0.33 per common share.
  • 6Cash flow from operations improved significantly to $84 million, up from $47 million in the prior year period, largely due to tax-related cash movements.
  • 7Quest Diagnostics continues to execute its 'Invigorate' cost-saving program, aiming for $700 million in run-rate savings by the end of 2014.

Frequently Asked Questions

The acquisition of Solstas Lab Partners Group, completed on March 7, 2014, contributed $25 million to net revenues and $27 million to operating expenses in the first quarter of 2014. This acquisition, valued at $572 million, is part of Quest Diagnostics' strategy to expand its reach in the southeastern United States and is expected to add to goodwill and intangible assets on the balance sheet.

Net revenues decreased by 2.3% to $1.75 billion. This decline was attributed to several factors including a 2.1% decrease in Diagnostic Information Services (DIS) revenue, an estimated 2% negative impact from unseasonably harsh winter weather, and a 4.3% decrease in Diagnostic Solutions (DS) businesses revenue, partly due to the sale of the Enterix business in the previous year. Revenue per requisition also decreased by 2.8%.

The company is actively pursuing its 'Invigorate' program, designed to achieve significant cost savings. In the first quarter of 2014, SG&A expenses decreased by 7.4% due to headcount reductions and lower restructuring costs. The company also reported a decrease in cost of services due to lower compensation and benefit costs, despite an increase in facility cost allocation and higher operating costs from recent acquisitions.

While income from continuing operations saw a year-over-year decrease, the company's commitment to cost management and strategic initiatives like the Invigorate program aim to improve future profitability. Quest Diagnostics also demonstrated a commitment to shareholder returns by increasing its quarterly dividend by 10% and continuing its share repurchase program, indicating confidence in its financial position and future cash flows.